论文部分内容阅读
目的探讨从免疫供血浆者获得高效价甲型H1N1流感病毒抗体血浆,为制备人甲型H1N1流感免疫球蛋白和重症患者临床使用提供依据。方法用批签法核准的市场供应甲型H1N1流感疫苗对1947名供血浆者按规定免疫后第2、4、6周收集血浆并采用血凝抑制试验进行检测。结果经检测供血浆者抗体效价≥10以上达到99.2%,其中≥320—10240达到48.4%。结论供血浆者经一次甲型H1N1流感疫苗免疫后收集高效价甲流抗体血浆用于制备特异性免疫球蛋白或供重症患者临床使用是可行的。
OBJECTIVE: To investigate the plasma of antibody against high-titer influenza A (H1N1) virus from immunized blood plasma and to provide a basis for clinical use of preparing human immunoglobulin H1N1 and severe patients. Methods A total of 1947 plasma donors were collected at the 2nd, 4th, and 6th weeks after the vaccine was approved by the batch approval method, and were tested by hemagglutination inhibition test. Results The blood plasma antibody titer of ≥10 or more reached 99.2%, of which ≥320-10240 reached 48.4%. Conclusion It is feasible to collect plasma with high-titer A-value antibody after being immunized with a type A H1N1 influenza vaccine for the preparation of specific immunoglobulin for clinical use in critically ill patients.